J

Jinyu Bio-Technology Co Ltd
SSE:600201

Watchlist Manager
Jinyu Bio-Technology Co Ltd
SSE:600201
Watchlist
Price: 7.13 CNY -0.14% Market Closed
Market Cap: 8B CNY
Have any thoughts about
Jinyu Bio-Technology Co Ltd?
Write Note

Net Margin
Jinyu Bio-Technology Co Ltd

12.2%
Current
17%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.2%
=
Net Income
164.9m
/
Revenue
1.4B

Net Margin Across Competitors

Country CN
Market Cap 8B CNY
Net Margin
12%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.7B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Jinyu Bio-Technology Co Ltd
Glance View

Market Cap
8B CNY
Industry
Biotechnology

Jinyu Bio-Technology Co Ltd., a hallmark of scientific innovation and agricultural care, operates at the intersection of biotech and animal health services, focusing primarily on the production of vaccines for livestock. Founded with the vision to enhance animal well-being and agricultural productivity, the company's trajectory has been marked by a commitment to research and development. This dedication is evidenced by its expansive portfolio, which features an array of vaccines aimed at safeguarding livestock against prevalent and virulent diseases. By investing heavily in R&D, Jinyu ensures that its product offerings remain at the frontier of technological advancement and efficacy. The company's modern facilities, equipped with state-of-the-art technology, facilitate the production of high-quality vaccines that adhere to international standards. The company's business model is intricately tied to its strategic positioning within the agricultural ecosystem. By catering to a critical segment—livestock and poultry farmers—Jinyu not only supplies essential vaccines but also provides veterinary services and support, ensuring a holistic approach to animal health. This dual role as a product supplier and service provider enables Jinyu Bio-Technology Co Ltd. to forge long-lasting relationships with its clientele, enhancing customer loyalty and creating a stable revenue stream. Moreover, its efforts in capturing emerging markets, particularly in regions where agricultural development is accelerating, signal a forward-thinking approach that seeks to tap into new growth avenues. Through these strategies, Jinyu continues to reinforce its stature as a pivotal player in the animal health domain, working diligently to marry profitability with sustainable agricultural development.

Intrinsic Value
10.74 CNY
Undervaluation 34%
Intrinsic Value
Price
J

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.2%
=
Net Income
164.9m
/
Revenue
1.4B
What is the Net Margin of Jinyu Bio-Technology Co Ltd?

Based on Jinyu Bio-Technology Co Ltd's most recent financial statements, the company has Net Margin of 12.2%.